EULAR 2017
Tofacitinib Goes Head-to-Head with Adalimumab in Rheumatoid Arthritis Study
Xeljanz and Xeljanz XR are Janus kinase (JAK) inhibitors indicated to treat moderately to severely active rheumatoid arthritis when methotrexate therapy is inadequate.
